Clinuvel Pharmaceuticals Ltd.Clinuvel Pharmaceuticals Ltd.Clinuvel Pharmaceuticals Ltd.

Clinuvel Pharmaceuticals Ltd.

No trades
See on Supercharts
Next report date
Report period
H2 2024
EPS estimate
0.30USD
Revenue estimate
‪37.48 M‬USD
Market capitalization
‪477.07 M‬USD
‪20.59 M‬USD
‪52.68 M‬USD
Beta (1Y)
0.44

About CLINUVEL PHARMACEUTICALS LIMITED

CEO
Philippe Jacques Wolgen
Headquarters
Melbourne
Founded
1999
FIGI
BBG000FL1WL1
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.